Back to announcement
20250630_OMED_Laporan Informasi dan Fakta Material_31909990_lamp2.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 2
Page 1
OMED Sets Strategic Direction for 2025: Share Buyback
and International Expansion
Press Release
Kabupaten Sidoarjo, 26 Juni 2025
PT Jayamas Medica Industri Tbk (“OMED”), a leading medical device company in
Indonesia under the “OneMed” brand, today held its Annual General Meeting of
Shareholders (AGMS), Extraordinary General Meeting of Shareholders (EGMS), and
Public Expose at Shangri-La Surabaya. During this event, OMED reaffirmed its growth
optimism through solid financial performance and a global market expansion strategy.
AGMS and EGMS Resolutions
At the AGMS, shareholders approved the Company’s Annual Report for the fiscal year
ended December 31, 2024, including the ratification of the consolidated financial
statements and granted full discharge (acquit et de charge) to the Board of Directors
and Board of Commissioners for the management and supervision conducted during
the period. The AGMS also approved the appropriation of 2024 net profit, including a
cash dividend of IDR 3.57 per share, totaling IDR 96,600,094,500 to be distributed to
shareholders.
In the EGMS, shareholders approved the Company’s plan to initiate a share buyback
program with a maximum value of IDR 5 billion during the period from June 27, 2025,
to June 27, 2026. This buyback is expected to reinforce market confidence in the
Company’s long-term prospects and support the employee share ownership program,
thereby increasing employee participation in the Company’s performance growth.
Consistent Financial Growth
Throughout 2024, revenue increased to IDR 1.88 trillion (up from IDR 1.73 trillion in
2023), with net profit rising to IDR 324 billion and a net profit margin of 17.2%. This
growth reflects the success of the Company’s product diversification and operational
efficiency strategies.
In the first quarter of 2025, the Company continued to record positive performance,
with revenue reaching IDR 436.3 billion, a 2.1% increase compared to the same period
the previous year. EBITDA for the period stood at IDR 98.4 billion with a margin of
22.6%, while net profit was IDR 73.1 billion with a margin of 16.8%.
Production Innovation: E-Beam Machine Operation
As part of its efforts to enhance production capacity and efficiency, PT Jayamas
Medica Industri Tbk (OMED) has obtained an operational license from the Nuclear
Page 2
Energy Regulatory Agency (BAPETEN) to operate its electron beam (E-Beam) machine. This was announced by Operations Director Leonard Hariadi Hartanto during the Public Expose on June 26, 2025. The E-Beam machine is used for sterilization and complements the existing ETO (Ethylene Oxide) sterilization facility at the Mojoagung Plant. This technology enables product sterilization in less than one minute—significantly faster than the ETO method, which takes 8 to 12 hours—with minimal residual waste. This facility is expected to accelerate production time and enhance the competitiveness of OMED’s products, especially for export markets. Global Partnerships and Expansion Strategy OMED is also actively pursuing global partnerships, including with Germany’s Fresenius-Kabi, as well as companies from Japan, France, and India, through joint manufacturing and co-branding collaborations to strengthen its domestic market position. “We are optimistic about the growth prospects of the medical device industry, supported by increasing public health awareness and the rising need for healthcare facilities,” said OMED President Director Dra. Herlien Sri Ariani. Entering 2025, OMED has begun expanding production capacity for exports, with a primary focus on the United States market, in response to growing global demand for medical devices and geopolitical dynamics that drive supply diversification. “Global market expansion is part of our long-term strategy to respond to international market dynamics and enhance the competitiveness of our products,” added Louis Krisnadi Hartanto, Director of Marketing and Sales. “OMED will continue to uphold transparency and maintain strong relationships with all stakeholders to achieve sustainable growth and deliver added value to society and shareholders,” concluded Eka Suwignyoo, the Company’s Finance Director. For more information, contact: Investor Relations PT Jayamas Medica Industri Tbk Email: ir@onemed.co.id Website: http://www.onemed.co.id
Names mentioned 5 people and organisations named in the text · linked when the evidence is strong
unresolved
person
Dra. Herlien Sri Ariani. Entering
p.2 ×2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.